Antipsychotic-induced weight gain is an important issue in the treatment of psychotic
illnesses, and affects 80% of individuals being treated with antipsychotic drugs. However …

Background: Debate continues about the comparative benefits and harms of first-generation
antipsychotics (FGAs) and second-generation antipsychotics (SGAs) in treating …

Background: Aripiprazole is a novel antipsychotic for the management of schizophrenia.
This study investigated the efficacy, safety, and tolerability of aripiprazole in preventing …

Importance Long-acting injectable antipsychotics are used to reduce medication
nonadherence and relapse in schizophrenia-spectrum disorders. The relative effectiveness …

Objectives: To review current evidence for the hypothesis that treatment with antipsychotic
medications may be associated with increased risks for weight gain, insulin resistance …

Background: A panel of academic psychiatrists and pharmacists, clinicians from the Texas
public mental health system, advocates, and consumers met in June 2006 in Dallas, Tex., to …

OBJECTIVE: The first episode of psychotic illness is a key intervention point. The initial
experience with medication can affect willingness to accept treatment. Further, relapse …

Aripiprazole is a novel atypical antipsychotic for the treatment of schizophrenia. It is a D2
receptor partial agonist with partial agonist activity at 5-HT1A receptors and antagonist …

These guidelines for the biological treatment of schizophrenia were developed by an
international Task Force of the World Federation of Societies of Biological Psychiatry …

Objective: Most previous studies of the incidence of tardive dyskinesia with atypical
antipsychotics compared with conventional antipsychotics have not had tardive dyskinesia …